Clinical Trial Update: TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating BIBF 1120 vs placebo in chemorefractory metastatic colorectal cancer treated with mFOLFOX6.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• BIBF 1120 (nintedanib)

Snippet

Sponsor: Martin-Luther-Universität Halle-Wittenberg | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED